Vertex Energy, Inc. (NASDAQ:VTNR) had its price objective cut by Imperial Capital from $8.50 to $5.50 in a research report released on Tuesday morning. Imperial Capital currently has an outperform rating on the stock. On Friday shares of Vertex Energy, Inc. (NASDAQ:VTNR) closed at $3.48. Company’s sales growth for last 5 years was 20.00% and EPS growth for next 5 years is recorded as 20.00%.
On 16 January, Johnson & Johnson (NYSE:JNJ) announced the formation of consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical Companies to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than €100 million from the Ebola+ programme to support the development, manufacturing and patient education for the vaccine regimen. Johnson & Johnson (NYSE:JNJ) in last trading activity decreased -2.19% to close at $100.14. Company weekly performance is -2.02% while its quarterly performance stands at -4.52%. Johnson & Johnson (NYSE:JNJ) is -8.12% away from its 52 week high.
On 29 January, Aviat Networks, Inc. (NASDAQ:AVNW) reported preliminary financial results for the second quarter of fiscal year 2015, which ended December 26, 2014. For the second quarter of fiscal year 2015, revenue was $92.5 million, compared with $85.8 million in the year-ago quarter. Aviat reported net loss, including discontinued operations, of $(3.3) million, or $(0.05) per share, compared with a net loss of $(9.9) million, or $(0.16) per share, in the year-ago quarter. On last trading day Aviat Networks, Inc. (NASDAQ:AVNW) decreased -7.91% to close at $1.28. Its volatility for the week is 8.30% while volatility for the month is 7.02%. AVNW’s sales growth for past 5 years was -12.60% and its EPS growth for past 5 years was 32.20%. Aviat Networks, Inc. (NASDAQ:AVNW) monthly performance is -13.51%.
Bristol-Myers Squibb Company (NYSE:BMY) announced that the US Food and Drug Administration (FDA) has approved its drug Evotaz as a fixed-dose combination of atazanavir, cobicistat, and other antiretroviral agents to treat adult patients with human immunodeficiency virus (HIV-1). On Friday shares of Bristol-Myers Squibb Company (NYSE:BMY) closed at $60.27. Company’s sales growth for last 5 years was -1.50% and EPS growth for next 5 years is recorded as 12.38%.
On 29 January, Bellatrix Exploration Ltd. (NYSE:BXE) said that it is cutting its 2015 capital budget for a third time, from $300 million to $200 million, joining a lengthening line of Calgary companies trying to preserve balance sheet strength in view of low oil and gas prices. On last trading day Bellatrix Exploration Ltd. (NYSE:BXE) advanced 5.73% to close at $2.03. Its volatility for the week is 11.56% while volatility for the month is 9.19%. Bellatrix Exploration Ltd. (NYSE:BXE) monthly performance is -43.30%.